Related Experiment Video
Updated: Aug 14, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[A case of ascities decrease in malignant peritoneal mesothelioma by weekly intra-peritoneal administration of
Katsunori Ami1, Takeshi Nagahama, Masayuki Andou
1Division of Surgery, Tokyo Metropolitan Toshima Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|December 1, 2005
Summary
This case study details malignant peritoneal mesothelioma (MPM) in a 63-year-old man. Intra-peritoneal chemotherapy effectively managed ascites, offering a potential treatment strategy for this rare cancer.
Area of Science:
- Oncology
- Pathology
Background:
- Malignant peritoneal mesothelioma (MPM) is a rare and aggressive cancer.
- Diagnosis and management of MPM present significant challenges, particularly in controlling ascites.
Observation:
- A 63-year-old male presented with weight loss and abdominal distension.
- Imaging revealed a large abdominal mass, extensive ascites, and omental cake.
- Histological diagnosis confirmed MPM via positive calretinin staining.
Findings:
- The patient received intra-peritoneal chemotherapy with cisplatin and paclitaxel.
- This treatment led to decreased ascites and improved oral intake.
- Omental cake remained unchanged, indicating limited impact on tumor bulk.
Implications:
- Intra-peritoneal chemotherapy demonstrates efficacy in managing ascites in MPM.
- This approach may offer a superior method for controlling malignant ascites compared to other treatments.
- Further research is warranted to optimize treatment strategies for MPM.
